VectivBio (VECT) Short Interest Ratio & Short Volume

Short interest is the volume of VectivBio shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 77,600 shares of VECT short. 0.27% of VectivBio's shares are currently sold short. Learn More on VectivBio's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.27% of VectivBio's floating shares are currently sold short.

VectivBio saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 77,600 shares, a decrease of 21.3% from the previous total of 98,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

VectivBio currently has issued a total of 34,020,000 shares. Some of VectivBio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. VectivBio currently has a public float of 28,830,000 shares.

0.27% of VectivBio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to VectivBio: Apellis Pharmaceuticals, Inc. (23.14%), Biohaven Ltd. (9.05%), Kymera Therapeutics, Inc. (13.52%), ImmunityBio, Inc. (58.08%), Mirum Pharmaceuticals, Inc. (16.96%), CG Oncology, Inc. (19.74%), NewAmsterdam Pharma (8.30%), Bausch Health Companies Inc. (3.09%), Belite Bio, Inc (0.22%), Beam Therapeutics Inc. (23.74%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.80 billion), Canadian Natural Resources Limited ($3.69 billion), Charter Communications, Inc. ($2.95 billion), Occidental Petroleum Co. ($2.78 billion), Moderna, Inc. ($2.38 billion), Palantir Technologies Inc. ($2.29 billion), T. Rowe Price Group, Inc. ($2.19 billion), Coinbase Global, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($2.02 billion), and Verisk Analytics, Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling VECT is an investing strategy that aims to generate trading profit from VectivBio as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for VectivBio occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VECT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VECT, twice per month. The most recent reporting period available is June, 15 2023.